Senator Leahy Urges NIH to Use March-In Rights on Myriad BRCA Test

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

Leahy, PatrickOn Friday, Sen. Patrick Leahy (D-VT) sent a letter to Dr. Francis Collins, the Director of the National Institutes of Health (NIH), "to urge [the Director] to consider using march-in rights under the Bayh-Dole Act to ensure greater access to genetic testing for breast and ovarian cancer."  The Bayh-Dole Act, which was enacted in 1980, created a uniform patent policy among the many federal agencies that fund research, enabling small business and non-profit organizations -- including universities -- to retain title to inventions made under federally funded research programs.  In commemorating the Act's 30th anniversary in 2010, the U.S. Patent and Trademark Office noted that "[t]he legislation is credited with the creation of thousands of new companies and billions of dollars of direct benefits to the U.S. economy" (see "USPTO Recognizes 30th Anniversary of Bayh-Dole Act").

As a result of the concern that U.S. taxpayers should not have to pay businesses for inventions that the public has already paid for, legislators added a section to the Act that gave the government "march-in" rights.  Recently, a handful of groups filed a petition with the NIH requesting the agency to exercise these march-in rights over the anti-AIDS drug ritonavir, exclusively sold by Abbott Laboratories (see "Groups Petition for NIH Exercise of March-in Rights over Abbott Laboratories' Norvir®," which includes a discussion of the statute and regulation governing the exercise of the government's march-in rights under the Bayh-Dole Act, as well as a recent history of requests that the government exercise such rights).

In encouraging the NIH to exercise its march-in rights with respect to the Myriad's BRCA test, Sen. Leahy (above right) indicates that:

Myriad's genetic test, which was developed with federally-funded research, is truly important for public health.  Myriad is the only provider of this test because it is covered by patent protection.  Unfortunately, testimony before the United States Patent and Trademark (USPTO) revealed that Myriad does all of this testing in-house, and charges between $3,000 and $4,000.

The letter notes that while the Supreme Court determined last month in Association for Molecular Pathology v. Myriad Genetics, Inc. that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, the Court also held that cDNA is patent eligible because it is not naturally occurring (albeit with the caveat, which the letter does not address, that a "very short series of DNA may have no intervening introns to remove when creating cDNA," and therefore, "a short strand of cDNA may be indistinguishable from natural DNA").  "As a result," Sen. Leahy suggests that "Myriad may continue to be the only company able to provide women with the genetic testing they need to make important health care decisions."

National Institutes of HealthSen. Leahy explains that because "the Bayh-Dole Act . . . gives the government tools, known as 'march-in rights,' to provide greater access to the subject invention in appropriate situations," "[t]he government can require the patent holder to grant a license to the patent on reasonable terms."  He notes that "[i]f the patent owner refuses, the government can directly license the patent in limited circumstances, including if it 'is necessary to alleviate health or safety needs which are not reasonably satisfied' by the patentee."  Indicating that "Myriad's patents were based in part on federally-funded research," and stating that the health benefits and healthcare cost savings of genetic testing for breast and ovarian cancer are clear, Sen. Leahy expresses "concern that the health needs of the public are not reasonably satisfied by the patentee in this situation because testimony presented to the USPTO made clear that many women are not able to afford the testing provided by Myriad."  He therefore encourages the Director to consider using the government's march-in rights with respect to the Myriad's BRCA test.

Interestingly, of the ten patents that Myriad recently asserted against Ambry Genetics (see "Myriad Genetics Files Suit Against Ambry Genetics for Genetic Diagnostic Testing of BRCA Genes"), only two (U.S. Patent Nos. 5,747,282 and 5,753,441) are assigned (on their face) to the U.S. government (as well as to Myriad and the University of Utah Research Foundation).  Of the remaining patents, one (U.S. Patent No. 5,709,999) is assigned to Myriad, the Centre de Recherche du Chul (Sainte-Foy, Canada), and the Cancer Institute (Tokyo, Japan); two (U.S. Patent Nos. 5,837,492 and 6,033,857) are assigned to Myriad, Endo Recherche, Inc. (Sainte-Foy, Canada), HSC Research & Development Ltd. (Toronto, Canada), and the Trustees of the University of Pennsylvania; three (U.S. Patent Nos. 5,654,155, 5,750,400, and 6,051,379) are assigned to OncorMed, Inc.; one (U.S. Patent No. 6,951,721) is assigned to Gene Logic Inc.; and one (U.S. Patent No. 7,250,497) is assigned to Myriad alone.  A search of the USPTO's Assignments on the Web for Patents (AOTW-P) database indicates that Myriad assigned the '999, '492, and '857 patents to the University of Utah Research Foundation, and that the '155, '400, '379, and '721 patents are assigned to Gene Logic Inc. and Myriad.

Patent Docs thanks Hal Wegner for alerting the patent community to Sen. Leahy's letter.

 

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.